6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension

American Journal of Gastroenterology

Volumn 102, Issue 11, 2007, Pages 2495-2503

  Ferlitsch, Arnulf ^a   Teml, Alexander ^a,b   Reinisch, Walter ^a   Ulbrich, Gregor ^a   Wrba, Fritz ^a   Homoncik, Monika ^a   Gangl, Alfred ^a   Peck Radosavljevic, Markus ^a   Vogelsang, Harald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; HOMOCYSTEINE; INFLIXIMAB; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TIOGUANINE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ENTERITIS; ESOPHAGUS VARICES; FEMALE; FOLIC ACID BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMODYNAMICS; HEPATIC VEIN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HYPERPLASIA; LONG TERM CARE; MALE; OPTIMAL DRUG DOSE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT DURATION; VENOUS PRESSURE; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY; FEMALE; FOCAL NODULAR HYPERPLASIA; HUMANS; HYPERTENSION, PORTAL; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; THIOGUANINE;

EID: 35448929759     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01530.x     Document Type: Article

References (49)

1. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004 13 : 563 7.
2. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30-year review. Gut 2002 50 : 485 9.
3. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: Clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007 46 : 187 208.
4. Travis SP, Stange EF, Lemann M, et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: Current management. Gut 2006 55 (Suppl 1 i16-35.
5. Elion GB. Historical background of 6-mercaptopurine. Toxicol Ind Health 1986 2 : 1 9.
6. Lennard L, Davies HA, Lilleyman JS. Is 6-TG more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993 68 : 186 90.
7. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001 7 : 181 9.
8. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003 98 : 1058 63.
9. Herrlinger KR, Deibert P, Schwab M, et al. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003 17 : 1459 64.
10. Deibert P, Dilger K, Fischer C, et al. High variation of tioguanine absorption in patients with chronic active Crohn's disease. Aliment Pharmacol Ther 2003 18 : 183 9.
11. Bonaz B, Boitard J, Marteau P, et al Getaid. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003 18 : 401 8.
12. Derijks LJ, de Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: A short-term safety assessment. Eur J Gastroenterol Hepatol 2003 15 : 63 7.
13. Cheung TK, Florin TH. 6-Thioguanine: A new old drug to procure remission in inflammatory bowel disease. Intern Med J 2003 33 : 44 6.
14. Teml A, Schwab M, Harrer M, et al. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol 2005 40 : 1205 13.
15. Dubinsky MC, Vasiliaukas EA, Singh H, et al. 6-Thioguanine can cause serious liver injuries in inflammatory bowel disease patients. Gastroenterology 2003 125 : 298 303.
16. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005 43 : 303 9.
17. Geller SA, Dubinsky MC, Poordad FF, et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004 28 : 1204 11.
18. Teml A, Schwab M, Hommes DW, et al. A systematic survey evaluating 6-TG-related hepatotoxicity in patients with IBD. Clin Pharmacol Ther 2006 44 : 503.
19. Rulyak SJ, Saunders MD, Lee SD. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. J Clin Gastroenterol 2003 36 : 234 7.
20. Russmann S, Zimmermann A, Krahenbuhl S, et al. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001 13 : 287 90.
21. Daniel F, Cadranel JF, Seksik P, et al. Azathioprine-induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol 2005 29 : 600 3.
22. Klein R, Goller S, Bianchi L. Nodular regenerative hyperplasia (NRH) of the liver - a manifestation of "organ-specific antiphospholipid syndrome"? Immunobiology 2003 207 : 51 7.
23. Arvanitaki M, Adler M. Nodular regenerative hyperplasia of the liver. A review of 14 cases. Hepatogastroenterology 2001 48 : 1425 9.
24. Pezzullo L, Muretto P, De Rosa G, et al. Liver nodular regenerative hyperplasia after bone marrow transplant. Haematologica 2000 85 : 669 70.
25. Goritsas C, Roussos A, Ferti A, et al. Nodular regenerative hyperplasia in a rheumatoid arthritis patient without felty's syndrome. J Clin Gastroenterol 2002 35 : 363 4.
26. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990 11 : 787 97.
27. Wanless IR, Godwin TA, Allen F, et al. Nodular regenerative hyperplasia of the liver in haematologic disorders: A possible response to obliterative portal venopathy. Medicine 1980 59 : 367 79.
28. Krasinskas AM, Eghtesad B, Kamath PS, et al. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005 11 : 627 34.
29. Key NS, Kelly PM, Emerson PM, et al. Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia. Lancet 1987 2 : 1050 2.
30. Ravikumara M, Hill FG, Wilson DC, et al. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia: A dual-centre experience. J Pediatr Gastroenterol Nutr 2006 42 : 535 8.
31. Broxson EH, Dole M, Wong R, et al. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr Blood Cancer 2005 44 : 226 31.
32. Shepherd PCA, Fooks J, Gray R, et al. Thioguanine used in maintenance therapy for chronic myeloid leukemia causes non-cirrhotic portal hypertension. Br J Haematol 1991 79 : 185 92.
33. De Bruyne R, Portmann B, Samyn M, et al. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol 2006 44 : 407 10.
34. Piel B, Vaidya S, Lancaster D, et al. Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2004 125 : 410 1.
35. de Boer NK, Reinisch W, Teml A, et al. 6-Thioguanine treatment in inflammatory bowel disease: A critical appraisal by a European 6-TG working party. Digestion 2006 73 : 25 31.
36. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (Suppl A 5 36.
37. Wongcharatrawee S, Groszmann RJ. Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 2000 14 : 881 94.
38. Lim JK, Groszmann RJ. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: Is there still a role for hepatic venous pressure gradient measurement? Hepatology 2007 45 : 1087 90.
39. Peck-Radosavljevic M, Trauner M, Schreiber F. Austrian consensus on the definition and treatment of portal hypertension and its complications. Endoscopy 2005 37 : 667 73.
40. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007 May 15 Epub ahead of print.
41. Arnott ID, Ghosh S. Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: Possible endothelial cell injury. Eur J Gastroenterol Hepatol 2000 12 : 569 73.
42. de Boer N, Gilissen L, Derijks L, et al. Hepatotoxicity of long-term and low-dose 6-thioguanine in IBD. Gastroenterology 2006 Suppl 1 S1327.
43. Gilissen LP, Derijks LJ, Driessen A, et al. Toxicity of 6-thioguanine: No hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig Liver Dis 2007 39 : 156 9.
44. Buchel O, Roskams T, Van Damme B, et al. Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia. Gut 2005 54 : 1021 3.
45. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005 353 : 2254 61.
46. Breen DP, Marinaki AM, Arenas M, et al. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 2005 11 : 826 33.
47. de Boer NK, Mulder CJ, van Bodegraven AA. Nodular regenerative hyperplasia and thiopurines: The case for level-dependent toxicity. Liver Transpl 2005 11 : 1300 1.
48. Haboubi NY, Ali HH, Whitwell HL, et al. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: Light microscopy and ultrastructural observations. Am J Gastroenterol 1988 83 : 256 61.
49. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003 361 : 952 4.